HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G Portfolio Rationalization Brushes Off 20% Of Oral Care SKUs

This article was originally published in The Rose Sheet

Executive Summary

P&G completes the bulk of the portfolio rationalization it launched in 2014, shedding or restructuring more than half of its brands globally to focus on 10 core categories, says CFO Jon Moeller.

You may also be interested in...



P&G Ups Forecast On Beauty, Health Results, Despite 'A Lot Of Variability'

P&G beauty division's sales grow on premium skin care lines and despite price increases as health care sales grow 5% on volume, particularly in oral care. Net earnings in latest quarter grow 9% to $2.78bn as results prompt investor activity with share price slipping 2.7% in trading at nearly twice average volume.

P&G Extends Crest Toothpaste Line While Trimming Production Footprint

P&G says harmful plaque bacteria below the gum line evades "even the most the diligent brushers," The firm plans in 2020 to move manufacturing of hair, oral and personal care products from Iowa to a facility in West Virginia.

Ahead Of P&G Board Vote, Activist Investor Peltz Gains Endorsements

As Procter & Gamble prepares for a shareholder vote that could shake up its board and its strategies, proxy advisor Glass, Lewis & Co. recommends shareholders vote in favor of electing Trian Fund Management CEO Nelson Peltz, who's pressing the firm for dramatic operational changes.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS109113

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel